Found vs Yucca Health (2026): prices, structure, verdict

On tirzepatide, Yucca Health↗ is cheaper: $258 versus $289 a month all-in — a $31 monthly gap, $372 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Yucca Health is cheaper: $146 versus $289 a month all-in — a $143 monthly gap, $1,716 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Found: the record, condensed

Start with the load-bearing figure: $289 a month, all-in, is what Found charges for tirzepatide at the 10 mg basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Found is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

Start with the load-bearing figure: $289 a month, all-in, is what Found charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

Yucca Health: the record, condensed

Start with the load-bearing figure: $258 a month, all-in, is what Yucca Health charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $258 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #2 of 17 verified programs, with the floor $43/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $191 a month. A year at this figure: $3,096 monthly-billed.

Start with the load-bearing figure: $146 a month, all-in, is what Yucca Health charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $146 is the whole subscription, which makes Yucca Health unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #2 of 20 in the verified semaglutide index — $13/month above the floor (Oak Longevity, $133) — and sits $203 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $1,752.

Operationally at Yucca Health: shipping included; commitment 6-month term; cancellation 6-month term applies; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Yucca Health page · visit Yucca Health ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: Yucca Health at $258, Found at $289 — a $31 monthly spread that compounds to $372 over a maintenance year and $744 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $31 gap is exactly what it appears to be.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $146 (Yucca Health) against $289 (Found). $143 a month sounds survivable; $1,716 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $143 gap is exactly what it appears to be.

A way to feel the $31 monthly gap: over a year it funds 1.4 extra months at Yucca Health’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $744, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Found $289/mo month-to-month against Yucca Health $258/mo month-to-month. The order holds: Yucca Health leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Found $867 monthly; Yucca Health $774 monthly — best path favors Yucca Health by $93. 6 months: Found $1,734 monthly; Yucca Health $1,548 monthly — best path favors Yucca Health by $186. 12 months: Found $3,468 monthly; Yucca Health $3,096 monthly — best path favors Yucca Health by $372. 24 months: Found $6,936 monthly; Yucca Health $6,192 monthly — best path favors Yucca Health by $744.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Found $867 vs Yucca Health $438 — $429 to Yucca Health. 6 mo: Found $1,734 vs Yucca Health $876 — $858 to Yucca Health. 12 mo: Found $3,468 vs Yucca Health $1,752 — $1,716 to Yucca Health. 24 mo: Found $6,936 vs Yucca Health $3,504 — $3,432 to Yucca Health.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Found publishes “most states”; Yucca Health publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Found — none month-to-month; prepaid terms for lowest rate; membership recurs; prepaid terms are paid up front. Yucca Health — 6-month term; 6-month term applies.

Insurance: only Found does coverage work — decisive if there is any chance your plan covers a brand GLP-1, because a covered prescription beats both cash paths on this page.

Evidence: Found third-party reported (captured 2026-08-05); Yucca Health source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #6 and #2 of 17: between them lie 3 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #15 and #2 of 20: between them lie 12 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Found and Yucca Health

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Found: membership recurs; prepaid terms are paid up front; Yucca Health: 6-month term applies) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings